Fiche publication
Date publication
janvier 2016
Journal
Journal of immunology research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DUMORTIER Hélène
Tous les auteurs :
Sawaf M, Dumortier H, Monneaux F
Lien Pubmed
Résumé
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by B cell hyperactivity leading to the production of autoantibodies, some of which having a deleterious effect. Reducing autoantibody production thus represents a way of controlling lupus pathogenesis, and a better understanding of the molecular and cellular factors involved in the differentiation of B cells into plasma cells could allow identifying new therapeutic targets. Follicular helper T cells (TFH) represent a distinct subset of CD4(+) T cells specialized in providing help to B cells. They are required for the formation of germinal centers and the generation of long-lived serological memory and, as such, are suspected to play a central role in SLE. Recent advances in the field of TFH biology have allowed the identification of important molecular factors involved in TFH differentiation, regulation, and function. Interestingly, some of these TFH-related molecules have been described to be dysregulated in lupus patients. In the present review, we give an overview of the aberrant expression and/or function of such key players in lupus, and we highlight their potential as therapeutic targets.
Mots clés
Adult, Autoantibodies, immunology, B-Lymphocytes, immunology, Cell Differentiation, Germinal Center, cytology, Humans, Lupus Erythematosus, Systemic, immunology, Molecular Targeted Therapy, Plasma Cells, immunology, T-Lymphocytes, Helper-Inducer, immunology
Référence
J Immunol Res. 2016 ;2016:5767106
